Biotech firm raises $225m in PIPE funding plus $60m trust to advance immunology pipeline targeting atopic dermatitis.
Talawar Therapeutics will list on Nasdaq under ticker ‘TLWR’ after merging with JATT II Acquisition, raising $285m in total funding. The capital includes $225m from a PIPE round backed by Access Biotechnology, Bain Capital Life Sciences, and RA Capital Management, plus $60m held in trust.
The company aims to challenge Sanofi and Regeneron’s Dupixent in the atopic dermatitis market with its lead candidate, TALA-125, a bispecific antibody targeting IL-13 and IL-18. A Phase IIb trial is expected to begin in 2027, with interim data slated for late 2028. Two additional discovery-phase immunology assets are also in development.
Talawar’s CEO stated the drug could surpass current monotherapy efficacy by combining two validated mechanisms in a single molecule.